Actively Recruiting
Early Detection of Islet Autoantibodies to Predict Type 1 Diabetes in At-risk Children and Adolescents in Gulf Countries
Led by Sanofi · Updated on 2026-10-23
3500
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a method to detect Type 1 Diabetes T1D early in children and adolescents who have a first-degree relative with T1D. The study aims to establish standardized screening, monitoring, and data collection for pre-symptomatic T1D in line with international guidelines. The trial is designed as a diagnostic study lasting approximately 13 months with two main visits. Participants will have blood samples collected to test for autoantibodies related to T1D. If any autoantibodies are found, additional tests including another autoantibody test, HbA1C test, and either an Oral Glucose Tolerance Test OGTT or Continuous Glucose Monitoring CGM will be performed. These procedures are conducted during two visits the initial screening visit and a confirmatory visit three months later. During the study, participants will undergo these tests to monitor for early signs of T1D development. Researchers will measure the proportion of at-risk relatives who meet diagnostic criteria for early stages of T1D at baseline and after three months. They will also track acceptance and refusal rates for screening and follow-up. Participants will be monitored over the 13-month period with no investigational drugs administered, focusing on diagnostic procedures and data collection.
CONDITIONS
Brief Title
Early Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF)
Research Team
T
Trial Transparency email recommended (Toll free for US & Canada)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here